cyrilzakka/clinical-trials huggingface dataset:
A Strength-Based Intervention to Improve Job Interview Skills in Young Adults in a Community Setting

The investigators are looking to evaluate how effective a strength-based intervention may be in improving job interview skills in young adults. The investigators are examining the effects of this intervention in young adults who may have difficulty with job interviews, and who may want to improve these skills.

The investigators have developed KF-STRIDE, a promising web-based intervention which focuses on helping autistic transition age youth improve interview skills by 1) learning to identify their unique employable strengths, and 2) practice speaking about those strengths to potential employers in socially appropriate ways. The inability to express one's strengths to a potential employer can negatively affect interview performance and lead to difficulty with job obtainment. Importantly, KF-STRIDE is web-based, so it is highly scalable, and uses well-established principles of positive psychology. The investigators' pilot data evaluating KF-STRIDE in a lab-based setting indicates that after using KF-STRIDE, users experience increased knowledge of their personal strengths and improved job interview skills. However, KF-STRIDE's effectiveness in a real-world setting has not been established. Kessler Foundation (KF) Center for Autism Research will partner with Spectrum Works (or other community partner) (see letter of support) to implement and evaluate KF-STRIDE in a real-world setting. Spectrum Works is a non-profit organization which provides job training and employment opportunities to autistic youth. In the current study, KF-STRIDE will be implemented at Spectrum Works (or other community partner) by Spectrum Work staff members (trained by KF staff).

Eligibility Criteria:
Inclusion Criteria:

Lives in the United States of America Between the ages of 14-26 Speaks English well and at a 4th grade reading level

Exclusion Criteria:

Had a stroke, Traumatic Brain Injury, or neurological injury or disease in the past(like brain tumor or epilepsy) Has a history of significant psychiatric illness(like schizophrenia or psychosis) Has uncontrolled seizures or other unstable medical complications
The 'Wearing Off' Effect of DMT

This is a non-interventional, cross-sectional, qualitative study in which patients diagnosed with MS and clinicians with experience treating MS will be interviewed regarding patient experiences with the wearing off effect from ocrelizumab, natalizumab, and ofatumumab


Eligibility Criteria:
Inclusion Criteria:

Patients who attend the following criteria will be included:

1. Age ≥18;
2. Current resident of the country of interest (i.e., Germany, the UK, or the US);
3. Relapsing-remitting MS diagnosis confirmed by a clinician;
4. Currently taking at least one of the following DMTs for MS after the maintenance phase: ocrelizumab (Ocrevus®), natalizumab (Tysabri®), or ofatumumab (Kesimpta®);
5. Two or more consecutive ocrelizumab doses (Six or more consecutive natalizumab doses or Six or more consecutive ofatumumab doses);
6. Follow the approved dosing regimen (Ocrelizumab: every six months or Natalizumab: every month or Ofatumumab: every month);
7. Experienced reoccurring symptoms towards the end of the dosing cycle (i.e., the wearing off effect);
8. Willing and able to provide informed consent via a weblink, indicating they understand the study purpose and procedures and are willing to participate;
9. Able to read, understand, and communicate in English or German;
10. Willing and able to participate in a phone/web-based (remote) one-on-one interview, and to be audio-recorded;
11. Have an e-mail address and will have access to a computer or smartphone at the time of the interview to complete the electronic consent form.

Clinicians who attend the following criteria will be included:

1. Currently practices in one of the target countries (i.e., Germany, the UK, or the US);
2. Is a licensed clinician with a specialty in neurology;
3. Has prescribed at least one of the following DMTs within the last year: ocrelizumab (Ocrevus®), natalizumab (Tysabri®), or ofatumumab (Kesimpta®);
4. Has treated at least 16 MS patients within the last month;
5. Is personally responsible for treatment decisions for their patients;
6. Has followed patients treating MS with any of the three DMTs for a. Two or more consecutive ocrelizumab doses or b. Six or more consecutive natalizumab doses. c. Six or more consecutive ofatumumab doses;
7. Has treated patients who have experienced specific reoccurring symptoms towards the end of the dosing cycle (i.e., the wearing off effect);
8. Willing and able to provide informed consent via a weblink, indicating they understand the study purpose and procedures and are willing to participate;
9. Willing and able to participate in a phone/web-based interview, and to be audio-recorded.
10. Able to read, understand, and communicate in English

Exclusion Criteria:

Patients will be excluded from the enrollment if:

1. Has a diagnosis of clinically isolated MS syndrome, primary progressive MS, or secondary progressive MS;
2. Currently participates in an interventional MS clinical trial.

Clinicians will be excluded from the enrollment if are currently involved as a key opinion leader or receives funding from one of the drug manufacturers
Light-Scattering Spectroscopy for Detection of Breast Cancer

This pilot clinical trial studies light-scattering spectroscopy in finding disease in patients with stage II-III breast cancer. Diagnostic procedures, such as light-scattering spectroscopy, may help find and diagnose breast cancer

PRIMARY OBJECTIVES: I. To evaluate whether light-scattering spectroscopy can reliably distinguish between two subject groups: those with clinical stage II or stage III breast cancer and those without breast cancer.

OUTLINE: Patients undergo light-scattering spectroscopy of the breast in addition to standard of care as it relates to screening for breast cancer or treatment of breast cancer.

Eligibility Criteria:
Inclusion Criteria:

* Participants who are breast cancer free (mammogram "negative" within 1 month of testing) with the absence of clinical suspicion of breast cancer on physical exam or with clinical stage II or stage III breast cancer. PLEASE NOTE: Recruitment for this study is only limited to patients who are scheduled for a mammogram at USC. There is no compensation to participants.
* Provision of informed consent prior to any study-related procedures

Exclusion Criteria:

* Females with tattoos on either or both breasts
* Females with nipple piercings on either or both breasts
* Females with skin piercings (aka microdermal anchor surface or microdermal piercings) in either or both breasts
* Females unable to provide informed consent
* Females s/p treatment for breast cancer
Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal Subjects

A Phase 1 study to evaluate the pharmacokinetics of ITCA 650 in subjects with mild and moderate renal impairment compared to the pharmacokinetics of subjects with normal renal function


Eligibility Criteria:
Inclusion Criteria:

* Body mass index between 22 and 40 kg/m²
* Subjects meeting pre-defined estimated glomerular filtration rate criteria and creatinine clearance rate

  * Normal (≥90 mL/min/1.73 m2)
  * Mild (60-89 mL/min/1.73 m2)
  * Moderate (45-59 mL/min/1.73 m2)
  * Moderate (\>30-44 mL/min/1.73 m2)

Exclusion Criteria:

* History of acute metabolic complications
* Uncontrolled Hypertension
* History of Hypersensitivity to Exenatide
* Cardiovascular Disease
* History of Acute or chronic pancreatitis
* Personal or family history of Multiple endocrine neoplasia type 2
* History of Medullary thyroid cancer
* Severe renal failure, End stage renal disease or dialysis
Evaluate The Accuracy Of Breast MRI Biopsy In Diagnosing A Complete Tumor Response For Some Women Following Neoadjuvant Chemotherapy For Breast Cancer

The purpose of this study is to test the ability of a breast MRI biopsy to accurately diagnose a complete tumor response to the neoadjuvant chemotherapy (NAC) that the patient just finished. Numerous studies have shown that MRI has the highest accuracy for diagnosing a complete tumor response. The investigator wants to see if in a certain group of women who's breast cancer is no longer visible on the post-treatment MRI that the biopsy specimens from a MRI guided biopsy will accurately diagnose a complete tumor response to treatment which may in the future make breast surgery unnecessary in some women.


Eligibility Criteria:
Inclusion Criteria:

* Women age 18 years or older
* Confirmed histologic diagnosis of operable HER2 overexpressing (ER\<10%, PR\<10%, and HER2 2+ or FISH amplified) OR triple negative (ER\<10%, PR\<10%, and HER2 0/1+ or 2+/FISH not amplified) OR ER positive invasive ductal or invasive lobular breast cancer including MSKCC pathology confirmation
* Operable breast cancer treated with NAC undergoing either breast conservation or total Mastectomy who have had a post-NAC clinical bilateral breast MRI demonstrating a complete imaging response, which is defined as no residual tumor enhancement.
* No indication of distant metastases (M0)
* Tumor site amenable to MRI guided biopsy as determined by the radiologist
* Definitive surgery being performed at MSKCC within within 0-60 days of completing NAC
* ECOG performance status score of 0 to ≤ 2 and or KPS performance status score of 80% to 100%
* Women of childbearing potential (WOCBP) must not be pregnant.
* Women must not be breastfeeding
* Willing and able to provide informed consent and adhere to the study visit schedule and plan as specified in this protocol

Exclusion Criteria:

* Medical history and concurrent disease:

  * Prior history of treated breast cancer
  * Any underlying medical or psychiatric conditions, which in the opinion of the investigator, will make performing the study intervention hazardous or obscure the interpretation of the results
* Prohibited Treatments and/or Therapies:

  * Prior history of breast cancer surgery and/or radiotherapy.
Trial of Ultrasound Guided Femoral Nerve Block on Isolated Femur Fracture Using Echo Friendly Needles

This study aims to determine if there is any difference in the success rate of ultra-sound guided femoral nerve block performed with an echogenic needle versus a standard needle.

To date, the published information regarding ultrasound guided femoral nerve blocks (FNB) using echo friendly needle is very limited. More so, there is even less information regarding ultrasound guided nerve blocks using echogenic versus standard of care needles.

This study hopes to add to the general knowledge of pain management in the emergency department (ED) setting and provide a unique perspective on ultrasound-guided techniques using echogenic needles to enhance accuracy and success rate of nerve blocks in ED patients.

The study design will have two comparative arms; in both arms we use the same local anesthetic which is Bupivacaine 0.25% with epinephrine; in all cases a total of 15 mL will be injected around the femoral nerve. Once identified with ultrasound, 5 ml will be injected at lateral, medial, and posterior aspect of the nerve. The experimental arm will receive an FNB using an echogenic needle; and the control group will receive an FNB using standard of care needles.

Eligibility Criteria:
Inclusion Criteria:

* Patients who present to the emergency department (ED) with isolated femur fracture (no other injuries)
* Patients who are cognitively alert and are able to verbalize their pain using a visual analog scale (VAS)
* Patients who are mentally competent to consent for the study
* Patients who can communicate in English or Spanish

Exclusion Criteria:

* Gestation
* Prisoners
* Patients who cannot communicate in English or in Spanish
* Patients who have other significant injuries besides a femur fracture
* Patients who are cognitively impaired and/or unable to verbalize their pain using a visual analog scale (VAS)
* Patients with allergies to local anesthetics
* Patients with severe liver disease
* Patients with existing peripheral neuropathies in the affected limb
* Patients with history of complications from previous femoral blocks
* Patients with contraindications for needle insertion at inguinal area
* Local signs of infection
* Patient on anticoagulants and/or with history of coagulation disorders
Speech Therapy and Repetitive Transcranial Magnetic Stimulation Therapy in Post-stroke Anomic Aphasia

The aim of the study is to observe the effects of speech therapy and transcranial magnetic stimulation therapy in patients who develop anomic aphasia after stroke. Patients meeting the inclusion criteria will be randomly divided into groups. In the repetitive transcranial magnetic stimulation (rTMS) treatment group, a total of 10 sessions, 1 session per day, will be applied to the right inferior frontal gyrus area with a frequency of 1 Hz for 20 minutes. The control group patients will be given speech therapy in the same way, but no active magnetic stimulation will be given in rTMS sessions (sham application). Speech therapy will be given to each patient by the same physiotherapist, and the treatment will last a total of 10 days, 60 minutes a day. Minimental test (MMT), Ege aphasia test, aphasia quality of life scale (SAQOL-39) will be filled in to the patients before and after the treatment.


Eligibility Criteria:
Inclusion Criteria:

* Stroke diagnosed with cranial MR examination causing unilateral hemiplegia
* Post-stroke patients with anomic aphasia
* 40-70 years
* Being able to read the basic instructions
* Medically and neurologically stable patients

Exclusion Criteria:

* Clinical condition that will constitute a contraindication to TMS (metallic implant, Cardiac pacemaker, pregnancy, breastfeeding, epilepsy, head trauma...)
* Having previously had TMS treatment
* Presence of Life-threatening disease and/or active systemic disease (chronic disease, malignancy ...)
* Alcohol or drug addiction
* Presence of neurodegenerative or psychiatric disorders
* Pregnancy or breastfeeding status
* Severe cognitive impairment
* Having a history of previous epilepsy
* Visual and auditory impairment
Does Blood Flow Restriction Training Improve Quadriceps Function After Arthroscopic Knee Surgery?

The purpose of this study is to evaluate the effectiveness of physical therapy (PT) plus BFR training compared to PT alone (without BFR training) after ACL reconstruction in patients who require extended limited weight bearing through assessment of patient reported outcomes and functional testing. The hypothesis is that PT plus BFR training will mitigate the loss of quadriceps muscle cross-sectional area, strength, and function while also improving early clinical and functional results.


Eligibility Criteria:
Inclusion Criteria:

* Anterior cruciate ligament (ACL) reconstruction with concomitant meniscus or cartilage restoration procedures
* Adherence to modified weight bearing status before initiation of PT
* Expected participation in recreational or competitive sports after release to full activities

Exclusion Criteria:

* Unable to attend (or participate in) physical therapy
* Pregnancy
* Malignancy
* Fracture
* Peripheral vascular disease
* History of deep vein thrombosis (DVT)
Clinical Efficacy and Safety of Fecal Microbiota Transplantation

Changes in the fecal microbiota are known to be involved in the etiology of several diseases. The purpose of this study is to evaluate the effectiveness and safety of fecal microbiota transplantation (FMT) in diseases known to be associated with intestinal microbial inbalance. .

This registry will prospectively enroll 300 patients who undergo fecal microbiota transplantation(FMT) at 3 clinical center (Yeungnam university mecial center, Kyungpook national university hospital, Keimyung university dongsan medical center). Feces received from healthy donors are prepared as frozen feces according to a standardized protocol, and transplanted to recipients within 3 months. Next generation sequencing(NGS) is used to check the characteristics of the fecal microbiota of the donor stool, and to evaluate the efficacy by checking the change in the fecal microbium of recipient before and after transplantation. The data is documented for following diseases known to be related to microbium imbalance.

1. Recurrent or Refractory CDI Abdominal symptoms questionnaires, blood laboratory test(CBC, CRP, protein/albumin, AST/ALT, GTP, Total bilirubin/Direct bilirubin)
2. Irritable bowel syndrome, Functional dyspepsia Abdominal symptoms questionnaires, IBS diagnosis and food-related questionnaires, blood laboratory test(CBC, CRP, protein/albumin, AST/ALT, GTP, Total bilirubin/Direct bilirubin)
3. Inflammatory Bowel Disease Abdominal symptoms questionnaires, blood laboratory test(CBC, CRP, protein/albumin, AST/ALT, GTP, Total bilirubin/Direct bilirubin), fecal calprotectin, Colonoscopic examination(Mayo endoscopic subscore, CD-SES)
4. Non-alcoholic steatohepatitis, NASH Abdominal symptoms questionnaires, blood laboratory test(CBC, CRP, protein/albumin, AST/ALT, GTP, Total bilirubin/Direct bilirubin), BMI check
5. Obesity Abdominal symptoms questionnaires, blood laboratory test(CBC, CRP, protein/albumin, AST/ALT, GTP, Total bilirubin/Direct bilirubin), BMI check

Eligibility Criteria:
Inclusion Criteria:

* Those who have been diagnosed with disease to be studied and do not respond to exist treatments

  1. Ulcerative colitis, Crohn disease : Patient who does not responding to anti- TNF treatment for more than 3 month.
  2. Irritable bowel syndrome, Functional dyspepsia : Patient who does not responding to pharmacological therapies and serotonin uptake inhibitor for more than 6 month.
  3. Recurrent of Refractory CDI, NASH, Obesity : Patient who does not responding to treatment for more than 6 month.

Exclusion Criteria:

* Neutrophil (\<0.5 x 10\*9/L)
* Leukocytosis (\> 30.0 x 10\*9/L)
* Toxic megacolon confirmed in abdomen Xray
* Pregnant or lactating women
Orthopedic Oncology Surgery: Navigation, Intraoperative Imaging and Virtual Reality

Noninterventional, prospective study of patients operated on for musculoskeletal neoplasms designed to evaluate the quality of surgical margins achievable with the use of navigated Intraoperative CT


Eligibility Criteria:
Inclusion Criteria:

* Age: no limit
* Patients with musculoskeletal neoplasms predominantly in complex sites
* Patients who will have to undergo surgical resection/amputation for the management of their clinical case
* Preparation of preoperative planning discussed at DMT
* Surgery performed with the aid of Intraoperative CT Navigated
* Written informed consent

Exclusion Criteria:

- Inability to perform pre-post treatment assessment
Evaluation of Interstitial Lung Disease Severity in Patients With Antisynthetase Syndrome According to Specific Autoantibodies Profile

Antisynthetase syndrome (ASS) is an overlap connective tissue disease characterized by the presence of myositis-specific autoantibodies directed against tRNA-synthetases. Clinical manifestations are myositis, interstitial lung disease (ILD), Raynaud's phenomenon, mechanic's hands and polyarthritis. Clinical presentation varies between ASS patients. ASS is potentially life threatening due to lung involvement, especially in rapidly progressive forms. Anti-histidyl-tRNA synthetase (anti-Jo1) antibodies are the most frequently detected antibodies in ASS (60 % of patients). Anti-threonyl-tRNA synthetase (anti-PL7) and alanyl-tRNA synthetase (anti-PL12) antibodies are each detected in 10 % of patients approximatively. Anti-tRNA-synthetases antibodies are mutually exclusive.

Clinical heterogeneity of ASS patients appears to be associated with specific autoantibodies profile. Patients with anti-Jo1 antibodies have a more systemic presentation (especially with muscle involvement), whereas patients with anti-PL7 or anti-PL12 antibodies have more frequent and isolated ILD. If anti-PL7 and anti-PL12 antibodies are associated with more severe ILD and poorer survival is still matter of debate.

Aims of this study were to compare ILD severity at diagnosis and clinical course in patients with ASS according to antisynthetase autoantibodies types.


Eligibility Criteria:
Inclusion Criteria:

* Patients with antisynthetase syndrome according to Connors criteria

Exclusion Criteria:

* None
Chronic Infections on Articular Prostheses With C. Acnes Diagnosed by Specific PCR

Osteaoarticular infection due to C. acnes are known to be of late onset, causing chronic infection possibly pauci-symptomatic. Osteaoarticular infection due to C. acnes represents a diagnostic challenge, since C. acnes is slow and difficult to grow, and can also be considered a contaminant.A 16S universal PCR bacteriological diagnosis has been proposed but is lacking of sensitivity. A specific C. acnes PCR was developed in 2010, but is not used routinely.


Eligibility Criteria:
Inclusion Criteria:

* patients having had infection prothesis vith C. acnes identified by PCR

Exclusion Criteria:

* none
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics of HRS4800 in Healthy Subjects

The study is being conducted to assess the safety and tolerability of HRS4800 after multiple oral administration with different dose regimens in healthy subjects.


Eligibility Criteria:
Inclusion Criteria:

1. Able and willing to provide a written informed consent
2. Males and females aged between 18 years and 55 years at screening, inclusive.
3. Meet the weight standard
4. Agree to take effective contraceptive methods
5. No clinically significant abnormalities in medical history, general physical examination, vital signs, laboratory tests

Exclusion Criteria:

1. Severe infections, injuries or surgeries or plan to undergo any surgeries.
2. ALT, AST, ALP or total bilirubin level abnormal
3. Estimated Glomerular Filtration Rate (eGFR, using CKD-EPI Creatinine Equation) is abnormal
4. Subject's supine systolic BP is \>140 mmHg or \<90 mmHg; diastolic BP \>90 mmHg or \<40 mmHg at screening/baseline visits or before dosing.
5. Subjects with cardiac and Cerebrovascular Disease
6. Positive nicotine test
7. History of regular alcohol consumption in the past 1 month exceeding an average weekly intake of 21 standard drinks
8. Positive drug screening tests
9. Positive infectious diseases screening tests
10. plan to use of any other medicine during the trial
11. Whole blood donation or loss of more than 200 mL of blood within 1 month
12. blood transfusion in the past 2 months
13. History of allergy to the study drug or any component of it.
14. Can't accept assigned meals during the trial
15. Treatment with an investigational drug within 30 days (or 5 half-lives, whichever is longer) of dosing.
16. poor tolerance or difficult for vein blood collection
17. Other conditions or laboratory abnormality that may increase the risk associated with study participation